Literature DB >> 25071103

PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer?

Ingrid A Mayer, Carlos L Arteaga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25071103     DOI： 10.1200/JCO.2014.55.9591

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  16 in total

Review 1.  Research update on the anticancer effects of buparlisib.

Authors:  Jinshan Xing; Jun Yang; Yingjiang Gu; Jingyan Yi
Journal:  Oncol Lett       Date:  2021-02-09       Impact factor: 2.967

2.  Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Authors:  Jennifer M Giltnane; Katherine E Hutchinson; Thomas P Stricker; Luigi Formisano; Christian D Young; Monica V Estrada; Mellissa J Nixon; Liping Du; Violeta Sanchez; Paula Gonzalez Ericsson; Maria G Kuba; Melinda E Sanders; Xinmeng J Mu; Eliezer M Van Allen; Nikhil Wagle; Ingrid A Mayer; Vandana Abramson; Henry Gόmez; Monica Rizzo; Weiyi Toy; Sarat Chandarlapaty; Erica L Mayer; Jason Christiansen; Danielle Murphy; Kerry Fitzgerald; Kai Wang; Jeffrey S Ross; Vincent A Miller; Phillip J Stephens; Roman Yelensky; Levi Garraway; Yu Shyr; Ingrid Meszoely; Justin M Balko; Carlos L Arteaga
Journal:  Sci Transl Med       Date:  2017-08-09       Impact factor: 17.956

3.  A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).

Authors:  Ingrid A Mayer; Aleix Prat; Daniel Egle; Sibel Blau; J Alejandro Pérez Fidalgo; Michael Gnant; Peter A Fasching; Marco Colleoni; Antonio C Wolff; Eric P Winer; Christian F Singer; Sara Hurvitz; Laura García Estévez; Peter A van Dam; Sherko Kümmel; Christoph Mundhenke; Frankie Holmes; Naveen Babbar; Laure Charbonnier; Ivan Diaz-Padilla; Florian D Vogl; Dalila Sellami; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2019-02-05       Impact factor: 12.531

Review 4.  New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.

Authors:  Sherry X Yang; Eric Polley; Stanley Lipkowitz
Journal:  Cancer Treat Rev       Date:  2016-03-09       Impact factor: 12.111

5.  The Gene Mutation Spectrum of Breast Cancer Analyzed by Semiconductor Sequencing Platform.

Authors:  Yanhui Liu; Bo Yang; Xiaoyan Zhang; Quanfei Huang; Hailiang Liu
Journal:  Pathol Oncol Res       Date:  2018-11-16       Impact factor: 3.201

Review 6.  The phosphoinositide 3-kinase pathway and therapy resistance in cancer.

Authors:  Kristin K Brown; Alex Toker
Journal:  F1000Prime Rep       Date:  2015-02-03

Review 7.  Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.

Authors:  Ilenia Migliaccio; Luca Malorni; Christopher D Hart; Cristina Guarducci; Angelo Di Leo
Journal:  BMC Med       Date:  2015-03-05       Impact factor: 8.775

8.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Authors:  Bernard Pereira; Suet-Feung Chin; Oscar M Rueda; Hans-Kristian Moen Vollan; Elena Provenzano; Helen A Bardwell; Michelle Pugh; Linda Jones; Roslin Russell; Stephen-John Sammut; Dana W Y Tsui; Bin Liu; Sarah-Jane Dawson; Jean Abraham; Helen Northen; John F Peden; Abhik Mukherjee; Gulisa Turashvili; Andrew R Green; Steve McKinney; Arusha Oloumi; Sohrab Shah; Nitzan Rosenfeld; Leigh Murphy; David R Bentley; Ian O Ellis; Arnie Purushotham; Sarah E Pinder; Anne-Lise Børresen-Dale; Helena M Earl; Paul D Pharoah; Mark T Ross; Samuel Aparicio; Carlos Caldas
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

9.  Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.

Authors:  Meagan B Myers; Malathi Banda; Karen L McKim; Yiying Wang; Michael J Powell; Barbara L Parsons
Journal:  Neoplasia       Date:  2016-04       Impact factor: 5.715

10.  The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

Authors:  Ben O'Leary; Rosalind J Cutts; Yuan Liu; Sarah Hrebien; Xin Huang; Kerry Fenwick; Fabrice André; Sibylle Loibl; Sherene Loi; Isaac Garcia-Murillas; Massimo Cristofanilli; Cynthia Huang Bartlett; Nicholas C Turner
Journal:  Cancer Discov       Date:  2018-09-11       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.